We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biomarker Discovered for Hypervirulent Pathogen

By LabMedica International staff writers
Posted on 18 Jul 2018
There is no accurate method for distinguishing between the hypervirulent strain from the classical strain of Klebsiella pneumoniae (cKp), which is most often seen in the Western hemisphere, and is less virulent and usually causes infections in hospital settings.

Several biomarkers have been discovered that can accurately identify hypervirulent K. More...
pneumoniae (hvKp), a pathogen that infects completely healthy people and can cause blindness in one day and flesh-eating infections, brain abscesses and death in just a few days.

An international team of scientists led by those at the University at Buffalo (Buffalo, NY, USA) identified a biomarker to differentiate hvKp from cKp strains they chose to use clinical data to develop strain cohorts for evaluation, given that the inclusion of any bacterial genotypic or phenotypic information in the definition of strain cohorts could introduce bias. The hvKp-rich cohort consisted of 85 strains isolated from deidentified patients from Taiwan and the USA. Since most K. pneumoniae infections in the North America and the UK presumably are due to cKp strains, the 90 cKp-rich strain cohort was generated from randomly chosen, deidentified blood isolates from different countries.

Study isolates were assessed for the presence of 10 genes and markers for capsule types. These included several genes located on the virulence plasmid, which have been shown experimentally to contribute to hypervirulence in in vivo infection models. Two hypothetically discriminatory phenotypic traits were evaluated. Polymerase chain reactions (PCR)-based detection of various capsule types were performed using the Applied Biosystems GeneAmp PCR system 9700 instrument.

The scientists found that the genes peg-344, iroB, iucA, prmpA, and prmpA2 all demonstrated >0.95 diagnostic accuracy for identifying strains in the hvKp-rich cohort. Quantitative siderophore production of ≥ 30 µg/mL also strongly predicted strains as members of the hvKp-rich cohort (accuracy 0.96) and exhibited a hazard ratio of 31.7 for severe illness or death. The string test, a widely used marker for hvKp strains, performed less well, achieving an accuracy of only 0.90.

Thomas A. Russo, MD, a professor of medicine and senior author of the study said, “The advantage of identifying these genetic biomarkers is that they can be developed into rapid nucleic acid tests, and if approved by the US Food and Drug Administration, would then provide clinicians with an accurate method to quickly determine if a patient is suffering from an infection due to the classical or hypervirulent strain.” The study was published on June 20, 2018, in the Journal of Clinical Microbiology.

Related Links:
University at Buffalo


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.